{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:27:54Z","timestamp":1761920874292,"version":"3.37.3"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","award":["4-2803\/2019"],"award-info":[{"award-number":["4-2803\/2019"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det om H\u00e4lsa, Arbetsliv och V\u00e4lf\u00e4rd","doi-asserted-by":"publisher","award":["2007-1762"],"award-info":[{"award-number":["2007-1762"]}],"id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40273-021-01035-4","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T10:03:11Z","timestamp":1620640991000},"page":"835-851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-of-Illness Progression Before and After Diagnosis of Multiple Sclerosis: A Nationwide Register-Based Cohort Study in Sweden of People Newly Diagnosed with Multiple Sclerosis and a Population-Based Matched Reference Group"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4150-4275","authenticated-orcid":false,"given":"Chantelle","family":"Murley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6138-6427","authenticated-orcid":false,"given":"Petter","family":"Tingh\u00f6g","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9313-3413","authenticated-orcid":false,"given":"Kristina","family":"Alexanderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7386-6732","authenticated-orcid":false,"given":"Jan","family":"Hillert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7874-4243","authenticated-orcid":false,"given":"Emilie","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2578-1865","authenticated-orcid":false,"given":"Korinna","family":"Karampampa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"issue":"9","key":"1035_CR1","doi-asserted-by":"publisher","first-page":"e108599","DOI":"10.1371\/journal.pone.0108599","volume":"9","author":"C Ahlgren","year":"2014","unstructured":"Ahlgren C, Oden A, Lycke J. High nationwide incidence of multiple sclerosis in Sweden. PLoS One. 2014;9(9):e108599.","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"1035_CR2","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","volume":"9","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9(Suppl 1):S5-48. https:\/\/doi.org\/10.1016\/j.msard.2016.07.003.","journal-title":"Mult Scler Relat Disord."},{"issue":"11","key":"1035_CR3","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1212\/wnl.0000000000000768","volume":"83","author":"P Browne","year":"2014","unstructured":"Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83(11):1022\u20134. https:\/\/doi.org\/10.1212\/wnl.0000000000000768.","journal-title":"Neurology"},{"issue":"11","key":"1035_CR4","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1177\/1352458516681197","volume":"23","author":"A Manouchehrinia","year":"2017","unstructured":"Manouchehrinia A, Beiki O, Hillert J. Clinical course of multiple sclerosis: a nationwide cohort study. Mult Scler. 2017;23(11):1488\u201395. https:\/\/doi.org\/10.1177\/1352458516681197.","journal-title":"Mult Scler."},{"issue":"8","key":"1035_CR5","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1177\/1352458511403794","volume":"17","author":"C Ahlgren","year":"2011","unstructured":"Ahlgren C, Oden A, Lycke J. High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler. 2011;17(8):901\u20138. https:\/\/doi.org\/10.1177\/1352458511403794.","journal-title":"Mult Scler."},{"issue":"5","key":"1035_CR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00228-018-2429-1","volume":"74","author":"I Eriksson","year":"2018","unstructured":"Eriksson I, Komen J, Piehl F, Malmstrom RE, Wettermark B, von Euler M. The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations. Eur J Clin Pharmacol. 2018;74(5):663\u201370. https:\/\/doi.org\/10.1007\/s00228-018-2429-1.","journal-title":"Eur J Clin Pharmacol."},{"issue":"2_Suppl","key":"1035_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/1352458517708682","volume":"23","author":"L Brundin","year":"2017","unstructured":"Brundin L, Kobelt G, Berg J, Capsa D, Eriksson J, European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: results for Sweden. Mult Scler. 2017;23(2_Suppl):179\u201391. https:\/\/doi.org\/10.1177\/1352458517708682.","journal-title":"Mult Scler"},{"key":"1035_CR8","doi-asserted-by":"publisher","first-page":"102360","DOI":"10.1016\/j.msard.2020.102360","volume":"45","author":"T Heinonen","year":"2020","unstructured":"Heinonen T, Castr\u00e9n E, Luukkaala T, M\u00e4kinen K, Ruutiainen J, Kuusisto H. The retirement rate due to multiple sclerosis has decreased since 1995: a retrospective study in a Finnish central hospital. Mult Scler Relat Disord. 2020;45:102360. https:\/\/doi.org\/10.1016\/j.msard.2020.102360.","journal-title":"Mult Scler Relat Disord."},{"issue":"3","key":"1035_CR9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00415-018-8764-4","volume":"265","author":"E Landfeldt","year":"2018","unstructured":"Landfeldt E, Castelo-Branco A, Svedbom A, Lofroth E, Kavaliunas A, Hillert J. The long-term impact of early treatment of multiple sclerosis on the risk of disability pension. J Neurol. 2018;265(3):701\u20137. https:\/\/doi.org\/10.1007\/s00415-018-8764-4.","journal-title":"J Neurol."},{"issue":"3","key":"1035_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10198-017-0894-6","volume":"19","author":"H Gyllensten","year":"2018","unstructured":"Gyllensten H, Wiberg M, Alexanderson K, Norlund A, Friberg E, Hillert J, et al. Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age. Eur J Health Econ. 2018;19(3):435\u201346. https:\/\/doi.org\/10.1007\/s10198-017-0894-6.","journal-title":"Eur J Health Econ."},{"issue":"1","key":"1035_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.healthpol.2005.07.016","volume":"77","author":"R Tarricone","year":"2006","unstructured":"Tarricone R. Cost-of-illness analysis: what room in health economics? Health Policy. 2006;77(1):51\u20133.","journal-title":"Health Policy"},{"issue":"1","key":"1035_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.euroneuro.2011.05.001","volume":"22","author":"P Jennum","year":"2012","unstructured":"Jennum P, Wanscher B, Frederiksen J, Kjellberg J. The socioeconomic consequences of multiple sclerosis: a controlled national study. Eur Neuropsychopharmacol. 2012;22(1):36\u201343. https:\/\/doi.org\/10.1016\/j.euroneuro.2011.05.001.","journal-title":"Eur Neuropsychopharmacol."},{"issue":"5","key":"1035_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2217\/cer-2017-0077","volume":"7","author":"S Buijs","year":"2018","unstructured":"Buijs S, Krol M, de Voer G. Healthcare utilization and costs of multiple sclerosis patients in the Netherlands: a healthcare claims database study. J Comp Eff Res. 2018;7(5):453\u201362. https:\/\/doi.org\/10.2217\/cer-2017-0077.","journal-title":"J Comp Eff Res."},{"issue":"4","key":"1035_CR14","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/1352458517702549","volume":"24","author":"H Gyllensten","year":"2018","unstructured":"Gyllensten H, Wiberg M, Alexanderson K, Friberg E, Hillert J, Tingh\u00f6g P. Comparing costs of illness of multiple sclerosis in three different years: a population-based study. Mult Scler. 2018;24(4):520\u20138. https:\/\/doi.org\/10.1177\/1352458517702549.","journal-title":"Mult Scler."},{"issue":"3","key":"1035_CR15","doi-asserted-by":"publisher","first-page":"205521731878335","DOI":"10.1177\/2055217318783352","volume":"4","author":"H Gyllensten","year":"2018","unstructured":"Gyllensten H, Kavaliunas A, Alexanderson K, Hillert J, Tinghog P, Friberg E. Costs and quality of life by disability among people with multiple sclerosis: a register-based study in Sweden. Mult Scler J. 2018;4(3):2055217318783352. https:\/\/doi.org\/10.1177\/2055217318783352.","journal-title":"Mult Scler J."},{"issue":"1","key":"1035_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/1352458520914844","volume":"27","author":"H Tremlett","year":"2021","unstructured":"Tremlett H, Marrie RA. The multiple sclerosis prodrome: emerging evidence, challenges, and opportunities. Mult Scler. 2021;27(1):6\u201312. https:\/\/doi.org\/10.1177\/1352458520914844.","journal-title":"Mult Scler."},{"issue":"6","key":"1035_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/s1474-4422(17)30076-5","volume":"16","author":"JMA Wijnands","year":"2017","unstructured":"Wijnands JMA, Kingwell E, Zhu F, Zhao Y, Hogg T, Stadnyk K, et al. Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. Lancet Neurol. 2017;16(6):445\u201351. https:\/\/doi.org\/10.1016\/s1474-4422(17)30076-5.","journal-title":"Lancet Neurol."},{"issue":"8","key":"1035_CR18","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1177\/1352458512471877","volume":"19","author":"RA Marrie","year":"2013","unstructured":"Marrie RA, Yu N, Wei Y, Elliott L, Blanchard J. High rates of physician services utilization at least five years before multiple sclerosis diagnosis. Mult Scler. 2013;19(8):1113\u20139. https:\/\/doi.org\/10.1177\/1352458512471877.","journal-title":"Mult Scler."},{"issue":"14","key":"1035_CR19","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1177\/1352458516667567","volume":"22","author":"E Landfeldt","year":"2016","unstructured":"Landfeldt E, Castelo-Branco A, Svedbom A, Lofroth E, Kavaliunas A, Hillert J. Sick leave and disability pension before and after diagnosis of multiple sclerosis. Mult Scler. 2016;22(14):1859\u201366. https:\/\/doi.org\/10.1177\/1352458516667567.","journal-title":"Mult Scler."},{"issue":"8","key":"1035_CR20","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1177\/1352458518783662","volume":"25","author":"JMA Wijnands","year":"2018","unstructured":"Wijnands JMA, Zhu F, Kingwell E, Zhao Y, Ekuma O, Lu X, et al. Five years before multiple sclerosis onset: phenotyping the prodrome. Mult Scler J. 2018;25(8):1092\u2013101. https:\/\/doi.org\/10.1177\/1352458518783662.","journal-title":"Mult Scler J."},{"issue":"9","key":"1035_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.18553\/jmcp.2010.16.9.703","volume":"16","author":"CV Asche","year":"2010","unstructured":"Asche CV, Singer ME, Jhaveri M, Chung H, Miller A. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm. 2010;16(9):703\u201312. https:\/\/doi.org\/10.18553\/jmcp.2010.16.9.703.","journal-title":"J Manag Care Pharm."},{"key":"1035_CR22","unstructured":"Swedish Association of Local Authorities and Regions (Sveriges Kommuner och Regioner). Patient fees from the 1st January 2019 [in Swedish]. 2019. https:\/\/skl.se\/download\/18.188eec29168389d39d799531\/1547805025982\/avgifter_%C3%B6ppen_slutenvard_2019_inkl.missiv.pdf. Accessed 12 Nov 2019."},{"key":"1035_CR23","unstructured":"Dental and Pharmaceutical Benefits Agency (Tandv\u00e5rds- och L\u00e4kemedelsf\u00f6rm\u00e5nsverket). High cost protection [in Swedish]. 2020. https:\/\/www.tlv.se\/lakemedel\/hogkostnadsskyddet.html. Accessed 11 June 2020."},{"key":"1035_CR24","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450. https:\/\/doi.org\/10.1186\/1471-2458-11-450.","journal-title":"BMC Public Health"},{"key":"1035_CR25","unstructured":"National Board of Health and Welfare (Socialstyrelsen). The National Patient Register. 2018. http:\/\/www.socialstyrelsen.se\/register\/halsodataregister\/patientregistret\/inenglish. Accessed 30 Apr 2018."},{"issue":"7","key":"1035_CR26","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register: opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726\u201335. https:\/\/doi.org\/10.1002\/pds.1294.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"1035_CR27","unstructured":"Swedish Social Insurance Agency (F\u00f6rs\u00e4kringskassan). Social insurance in figures 2015. Stockholm: Swedish Social Insurance Agency; 2015. https:\/\/www.forsakringskassan.se\/wps\/wcm\/connect\/e37b4ff1-d5d2-42dc-896b-bac5c59390e6\/socialforsakringen_i_siffror_2015_engelsk.pdf?MOD=AJPERES. Accessed 10 Mar 2020."},{"key":"1035_CR28","unstructured":"Swedish Social Insurance Agency (F\u00f6rs\u00e4kringskassan). MiDAS: sickness benefit and rehabilitation benefit [in Swedish]. Stockholm: Swedish Social Insurance Agency; 2011."},{"key":"1035_CR29","unstructured":"Statistics Sweden (Statistiska centralbyr\u00e5n). Longitudinal integration database for sick leave and labour market studies (LISA) 1990\u20132013 [in Swedish]. \u00d6rebro: Statistics Sweden; 2016.\u00a0https:\/\/www.scb.se\/contentassets\/f0bc88c852364b6ea5c1654a0cc90234\/dokumentation-av-lisa.pdf. Accessed 10 Mar 2020."},{"issue":"4","key":"1035_CR30","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10654-019-00511-8","volume":"34","author":"JF Ludvigsson","year":"2019","unstructured":"Ludvigsson JF, Svedberg P, Olen O, Bruze G, Neovius M. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol. 2019;34(4):423\u201337. https:\/\/doi.org\/10.1007\/s10654-019-00511-8.","journal-title":"Eur J Epidemiol."},{"issue":"199","key":"1035_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/ane.12425","volume":"132","author":"J Hillert","year":"2015","unstructured":"Hillert J, Stawiarz L. The Swedish MS registry: clinical support tool and scientific resource. Acta Neurol Scand. 2015;132(199):11\u20139. https:\/\/doi.org\/10.1111\/ane.12425.","journal-title":"Acta Neurol Scand."},{"key":"1035_CR32","unstructured":"Swedish Association of Local Authorities and Regions (Sveriges Kommuner och Regioner). Cost per patient somatic [in Swedish]. https:\/\/skr.se\/ekonomijuridikstatistik\/statistik\/kostnadperpatientkpp\/kppsomatik.1077.html. Accessed 10 Mar 2020."},{"key":"1035_CR33","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"M Drummond","year":"2005","unstructured":"Drummond M. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford Medical Publications, Oxford University Press; 2005.","edition":"3"},{"issue":"8","key":"1035_CR34","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458517694432","volume":"23","author":"G Kobelt","year":"2017","unstructured":"Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123\u201336. https:\/\/doi.org\/10.1177\/1352458517694432.","journal-title":"Mult Scler."},{"key":"1035_CR35","unstructured":"Statistics Sweden (Statistiska centralbyr\u00e5n). Average monthly salary by sector 1992\u20132019. https:\/\/www.scb.se\/en\/finding-statistics\/statistics-by-subject-area\/labour-market\/wages-salaries-and-labour-costs\/salary-structures-whole-economy\/pong\/tables-and-graphs\/average-monthly-salary-by-sector\/. Accessed 22 July 2020."},{"key":"1035_CR36","unstructured":"Swedish Tax Authority (Skatteverket). Totals and percentages [in Swedish]. https:\/\/www.skatteverket.se\/privat\/skatter\/beloppochprocent.4.18e1b10334ebe8bc80004109.html. Accessed 28 Jan 2020."},{"key":"1035_CR37","unstructured":"Eurostat. HICP (2015 = 100) - annual data (average index and rate of change). https:\/\/appsso.eurostat.ec.europa.eu\/nui\/show.do?dataset=prc_hicp_aind&lang=en. Accessed 28 Jan 2020."},{"key":"1035_CR38","unstructured":"Eurostat. ECU\/EUR exchange rates versus national currencies. 2020. https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/tec00033\/default\/table?lang=en. Accessed 6 Nov 2020."},{"issue":"1","key":"1035_CR39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","volume":"73","author":"K Liang","year":"1986","unstructured":"Liang K, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13\u201322.","journal-title":"Biometrika"},{"key":"1035_CR40","unstructured":"Jones A. Models for health care. Health, Econometrics and Data Group (HEDG) Working Papers, HEDG, c\/o Department of Economics, University of York. 2010. https:\/\/EconPapers.repec.org\/RePEc:yor:hectdg:10\/01. Accessed 01 Apr 2021."},{"issue":"8","key":"1035_CR41","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/hec.1653","volume":"20","author":"B Mihaylova","year":"2011","unstructured":"Mihaylova B, Briggs A, O\u2019Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20(8):897\u2013916. https:\/\/doi.org\/10.1002\/hec.1653.","journal-title":"Health Econ."},{"issue":"4","key":"1035_CR42","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/aje\/kwf215","volume":"157","author":"J Hanley","year":"2003","unstructured":"Hanley J, Negassa A, Edwardes M, Forrester J. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol. 2003;157(4):364\u201375.","journal-title":"Am J Epidemiol."},{"issue":"7","key":"1035_CR43","doi-asserted-by":"publisher","first-page":"e024836","DOI":"10.1136\/bmjopen-2018-024836","volume":"9","author":"M Wiberg","year":"2019","unstructured":"Wiberg M, Murley C, Tingh\u00f6g P, Alexanderson K, Palmer E, Hillert J, et al. Earnings among people with multiple sclerosis compared to references, in total and by educational level and type of occupation: a population-based cohort study at different points in time. BMJ Open. 2019;9(7):e024836. https:\/\/doi.org\/10.1136\/bmjopen-2018-024836.","journal-title":"BMJ Open"},{"issue":"27","key":"1035_CR44","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1002\/sim.5879","volume":"32","author":"A Sjolander","year":"2013","unstructured":"Sjolander A, Greenland S. Ignoring the matching variables in cohort studies: when is it valid and why? Stat Med. 2013;32(27):4696\u2013708. https:\/\/doi.org\/10.1002\/sim.5879.","journal-title":"Stat Med."},{"issue":"6","key":"1035_CR45","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1111\/jdi.13308","volume":"11","author":"T Wu","year":"2020","unstructured":"Wu T, Yang F, Chan WWL, Lam CLK, Wong CKH. Healthcare utilization and direct medical cost in the years during and after cancer diagnosis in patients with type 2 diabetes mellitus. J Diabetes Investig. 2020;11(6):1661\u201372. https:\/\/doi.org\/10.1111\/jdi.13308.","journal-title":"J Diabetes Investig."},{"issue":"2","key":"1035_CR46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/1094428104263672","volume":"7","author":"G Ballinger","year":"2004","unstructured":"Ballinger G. Using generalized estimating equations for longitudinal data analysis. Org Res Methods. 2004;7(2):127\u201350. https:\/\/doi.org\/10.1177\/1094428104263672.","journal-title":"Org Res Methods."},{"issue":"1","key":"1035_CR47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/01.Mlr.0000039830.19812.29","volume":"41","author":"PA Fishman","year":"2003","unstructured":"Fishman PA, Goodman MJ, Hornbrook MC, Meenan RT, Bachman DJ, O\u2019Keeffe Rosetti MC. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care. 2003;41(1):84\u201399. https:\/\/doi.org\/10.1097\/01.Mlr.0000039830.19812.29.","journal-title":"Med Care."},{"issue":"5","key":"1035_CR48","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1097\/j.pain.0000000000001500","volume":"160","author":"S Lalic","year":"2019","unstructured":"Lalic S, Bell JS, Gyllensten H, Gisev N, Friberg E, Ilomaki J, et al. Trajectories of sickness absence and disability pension before and after opioid initiation for noncancer pain: a 10-year population-based study. Pain. 2019;160(5):1224\u201333. https:\/\/doi.org\/10.1097\/j.pain.0000000000001500.","journal-title":"Pain"},{"key":"1035_CR49","doi-asserted-by":"publisher","first-page":"102162","DOI":"10.1016\/j.msard.2020.102162","volume":"43","author":"M Paz-Zulueta","year":"2020","unstructured":"Paz-Zulueta M, Par\u00e1s-Bravo P, Cantarero-Prieto D, Bl\u00e1zquez-Fern\u00e1ndez C, Oterino-Dur\u00e1n A. A literature review of cost-of-illness studies on the economic burden of multiple sclerosis. Mult Scler Relat Disord. 2020;43:102162. https:\/\/doi.org\/10.1016\/j.msard.2020.102162.","journal-title":"Mult Scler Relat Disord."},{"issue":"7","key":"1035_CR50","doi-asserted-by":"publisher","first-page":"e0159129","DOI":"10.1371\/journal.pone.0159129","volume":"11","author":"O Ernstsson","year":"2016","unstructured":"Ernstsson O, Gyllensten H, Alexanderson K, Tingh\u00f6g P, Friberg E, Norlund A. Cost of illness of multiple sclerosis: a systematic review. PLoS One. 2016;11(7):e0159129. https:\/\/doi.org\/10.1371\/journal.pone.0159129.","journal-title":"PLoS One"},{"issue":"1","key":"1035_CR51","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1186\/s12913-017-2807-x","volume":"17","author":"A Sicras-Mainar","year":"2017","unstructured":"Sicras-Mainar A, Ruiz-Beato E, Navarro-Artieda R, Maurino J. Impact on healthcare resource utilization of multiple sclerosis in Spain. BMC Health Serv Res. 2017;17(1):854. https:\/\/doi.org\/10.1186\/s12913-017-2807-x.","journal-title":"BMC Health Serv Res."},{"issue":"1","key":"1035_CR52","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s41669-019-0150-3","volume":"4","author":"K Karampampa","year":"2020","unstructured":"Karampampa K, Gyllensten H, Yang F, Murley C, Friberg E, Hillert J, et al. Healthcare, sickness absence, and disability pension cost trajectories in the first 5 years after diagnosis with multiple sclerosis: a prospective register-based cohort study in Sweden. Pharmacoecon Open. 2020;4(1):91\u2013103. https:\/\/doi.org\/10.1007\/s41669-019-0150-3.","journal-title":"Pharmacoecon Open."},{"issue":"2","key":"1035_CR53","doi-asserted-by":"publisher","first-page":"205521731985838","DOI":"10.1177\/2055217319858383","volume":"5","author":"H Gyllensten","year":"2019","unstructured":"Gyllensten H, Kavaliunas A, Murley C, Alexanderson K, Hillert J, Tingh\u00f6g P, et al. Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden. Mult Scler J. 2019;5(2):2055217319858383. https:\/\/doi.org\/10.1177\/2055217319858383.","journal-title":"Mult Scler J."},{"key":"1035_CR54","unstructured":"National Board of Health and Welfare (Socialstyrelsen). National guidelines: care for multiple sclerosis and Parkinson's disease: support for steering and management [in Swedish]. Falun: National Board of Health and Welfare; 2016. https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/nationella-riktlinjer\/2016-12-1.pdf. Accessed 30 Apr 2020."},{"issue":"8","key":"1035_CR55","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40273-020-00917-3","volume":"38","author":"NH Ness","year":"2020","unstructured":"Ness NH, Schriefer D, Haase R, Ettle B, Ziemssen T. Real-world evidence on the patterns of increased societal economic relapse costs in patients with multiple sclerosis. Pharmacoeconomics. 2020;38(8):883\u201392. https:\/\/doi.org\/10.1007\/s40273-020-00917-3.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"1035_CR56","doi-asserted-by":"publisher","first-page":"e020392","DOI":"10.1136\/bmjopen-2017-020392","volume":"8","author":"C Murley","year":"2018","unstructured":"Murley C, Mogard O, Wiberg M, Alexanderson K, Karampampa K, Friberg E, et al. Trajectories of disposable income among people of working ages diagnosed with multiple sclerosis: a nationwide register-based cohort study in Sweden 7 years before to 4 years after diagnosis with a population-based reference group. BMJ Open. 2018;8(5):e020392. https:\/\/doi.org\/10.1136\/bmjopen-2017-020392.","journal-title":"BMJ Open"},{"issue":"11","key":"1035_CR57","doi-asserted-by":"publisher","first-page":"e012731","DOI":"10.1136\/bmjopen-2016-012731","volume":"6","author":"H Gyllensten","year":"2016","unstructured":"Gyllensten H, Wiberg M, Alexanderson K, Hillert J, Tingh\u00f6g P. How does work disability of patients with MS develop before and after diagnosis? A nationwide cohort study with a reference group. BMJ Open. 2016;6(11):e012731. https:\/\/doi.org\/10.1136\/bmjopen-2016-012731.","journal-title":"BMJ Open"},{"key":"1035_CR58","doi-asserted-by":"publisher","first-page":"102077","DOI":"10.1016\/j.msard.2020.102077","volume":"42","author":"C Murley","year":"2020","unstructured":"Murley C, Karampampa K, Alexanderson K, Hillert J, Friberg E. Diagnosis-specific sickness absence and disability pension before and after multiple sclerosis diagnosis: an 8-year nationwide longitudinal cohort study with matched references. Mult Scler Relat Disord. 2020;42:102077. https:\/\/doi.org\/10.1016\/j.msard.2020.102077.","journal-title":"Mult Scler Relat Disord."},{"issue":"6","key":"1035_CR59","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/s1474-4422(17)30127-8","volume":"16","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G. The neurodegenerative prodrome in multiple sclerosis. Lancet Neurol. 2017;16(6):413\u20134. https:\/\/doi.org\/10.1016\/s1474-4422(17)30127-8.","journal-title":"Lancet Neurol."},{"issue":"10","key":"1035_CR60","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1093\/brain\/awaa251","volume":"143","author":"MP Amato","year":"2020","unstructured":"Amato MP, Fonderico M, Portaccio E, Past\u00f2 L, Razzolini L, Prestipino E, et al. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain. 2020;143(10):3013\u201324. https:\/\/doi.org\/10.1093\/brain\/awaa251.","journal-title":"Brain"},{"issue":"7","key":"1035_CR61","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.clinthera.2011.05.049","volume":"33","author":"SM Curkendall","year":"2011","unstructured":"Curkendall SM, Wang C, Johnson BH, Cao Z, Preblick R, Torres AM, et al. Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy. Clin Ther. 2011;33(7):914\u201325. https:\/\/doi.org\/10.1016\/j.clinthera.2011.05.049.","journal-title":"Clin Ther."},{"issue":"4","key":"1035_CR62","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/apt.15889","volume":"52","author":"H Khalili","year":"2020","unstructured":"Khalili H, Everhov AH, Halfvarson J, Ludvigsson JF, Askling J, Myrelid P, et al. Healthcare use, work loss and total costs in incident and prevalent Crohn\u2019s disease and ulcerative colitis: results from a nationwide study in Sweden. Aliment Pharmacol Ther. 2020;52(4):655\u201368. https:\/\/doi.org\/10.1111\/apt.15889.","journal-title":"Aliment Pharmacol Ther."},{"issue":"8","key":"1035_CR63","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1023\/B:EJEP.0000036572.00663.f2","volume":"19","author":"JW Twisk","year":"2004","unstructured":"Twisk JW. Longitudinal data analysis: a comparison between generalized estimating equations and random coefficient analysis. Eur J Epidemiol. 2004;19(8):769\u201376.","journal-title":"Eur J Epidemiol."},{"key":"1035_CR64","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3389\/fneur.2020.00851","volume":"11","author":"M Magyari","year":"2020","unstructured":"Magyari M, Sorensen PS. Comorbidity in multiple sclerosis. Front Neurol. 2020;11:851. https:\/\/doi.org\/10.3389\/fneur.2020.00851.","journal-title":"Front Neurol."},{"issue":"24","key":"1035_CR65","doi-asserted-by":"publisher","first-page":"e2216","DOI":"10.1212\/wnl.0000000000008617","volume":"93","author":"S Binzer","year":"2019","unstructured":"Binzer S, McKay KA, Brenner P, Hillert J, Manouchehrinia A. Disability worsening among persons with multiple sclerosis and depression: a Swedish cohort study. Neurology. 2019;93(24):e2216\u201323. https:\/\/doi.org\/10.1212\/wnl.0000000000008617.","journal-title":"Neurology"},{"key":"1035_CR66","unstructured":"National Board of Health and Welfare (Socialstyrelsen). DRG: Foundational concepts and principles [in Swedish]. 2019. https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/dokument-webb\/klassifikationer-och-koder\/drg-grundlaggande-begrepp-och-principer.pdf. Accessed 30 July 2020."},{"issue":"4","key":"1035_CR67","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/s1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307\u201316. https:\/\/doi.org\/10.1016\/s1474-4422(20)30067-3.","journal-title":"Lancet Neurol."},{"issue":"6","key":"1035_CR68","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/rheumatology\/keq399","volume":"50","author":"I Filipovic","year":"2011","unstructured":"Filipovic I, Walker D, Forster F, Curry AS. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology. 2011;50(6):1083\u201390. https:\/\/doi.org\/10.1093\/rheumatology\/keq399.","journal-title":"Rheumatology"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01035-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-021-01035-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01035-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T14:22:06Z","timestamp":1725027726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-021-01035-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":68,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1035"],"URL":"https:\/\/doi.org\/10.1007\/s40273-021-01035-4","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"assertion":[{"value":"18 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Funding note is included and deleted from the Declarations section.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chantelle Murley, Kristina Alexanderson, and Emilie Friberg were partly funded by an unrestricted research grant from Biogen. Kristina Alexanderson has received unrestricted researcher-initiated grants from Biogen. Emilie Friberg has received unrestricted researcher-initiated grants from Celgene. Petter Tingh\u00f6g has previously received salaries partly funded by Biogen and has no conflicts of interest directly relevant to the content of this article. Korinna Karampampa has previously been employed and received salaries from Karolinska Institutet that were partly funded by Biogen, but not for conducting this study and has not received any salary from Karolinska Institutet or Biogen since October 2019. Currently Korinna Karampampa is only affiliated with Karolinska Institutet, not receiving any financial compensation for her involvement in this study. Korinna Karampampa is working full time at a biopharmaceutical company, Gilead Sciences AB. Jan Hillert received honoraria for serving on advisory boards for Biogen and Novartis and speaker\u2019s fees from Biogen, Merck-Serono, Bayer-Schering, Teva and Sanofi-Aventis. He has served as the principal investigator for projects sponsored by, or received unrestricted research support from, Biogen, Merck-Serono, TEVA, Novartis and Bayer-Schering. Jan Hillert\u2019s MS research is also funded by the Swedish Research Council.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval for the research project was obtained from the Regional Ethical Review Board in Stockholm, Dnrs: 2007\/762-31; 2009\/23-32; 2009\/1917-32; 2010\/466-32; 2011\/806-32; 2011\/1710-32; and 2014\/236-32. The study was performed in accordance with the tenants of the Declaration of Helsinki and later amendments. Informed consent from the research participants was not applicable owing to the use of pseudonymised data from total population administrative registers and that we do not hold individual details revealing the identity of the participants. Individuals included in the voluntary Swedish MS Registry provide consent for the neurologist to enter their information into the register for both clinical and research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No data are available. Please contact\u00a0Prof. Kristina\u00a0Alexanderson (<u>kristina.alexanderson@ki.se<\/u>)\u00a0about why the data, according to the General Data Protection Regulation, the Swedish Data\u00a0Protection Act, the Swedish Ethical Review Act and the Swedish Public Access to\u00a0Information and Secrecy Act, cannot be made available.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Data for this study were obtained by KA and JH. Data management and analysis were performed by CM. Statistical interpretation was conducted by CM, PT, EF and KK. The first draft of the manuscript was written by CM and all authors commented on versions of the manuscript. All authors have read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}